Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Reuben

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Science (New York, N.Y.)|September 16, 2017
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineLeore T Geller, Michal Barzily-Rokni, Tal Danino, et al.
Cancer Immunology Research|January 20, 2022
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16<sup>+</sup> CancersLauren E Colbert, Molly B El, Erica J Lynn, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
Nature|March 18, 2021
Identification of bacteria-derived HLA-bound peptides in melanomaShelly Kalaora, Adi Nagler, Deborah Nejman, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
Nature Communications|February 1, 2020
Comprehensive T cell repertoire characterization of non-small cell lung cancerAlexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Science (New York, N.Y.)|September 16, 2017
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineLeore T Geller, Michal Barzily-Rokni, Tal Danino, et al.
Cancer Immunology Research|January 20, 2022
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16<sup>+</sup> CancersLauren E Colbert, Molly B El, Erica J Lynn, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
Nature|March 18, 2021
Identification of bacteria-derived HLA-bound peptides in melanomaShelly Kalaora, Adi Nagler, Deborah Nejman, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
Nature Communications|February 1, 2020
Comprehensive T cell repertoire characterization of non-small cell lung cancerAlexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Pageof 14